Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | CCKBR | P32239 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4806085 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL16371592 | 0.77 | CYP11B1 (0.47) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL30054743 | 0.77 | CYP11B1 (0.40) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL11891095 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP19A1KMT2ASMN1; SMN2 | |
| SCHEMBL314908 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL25190881 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL27804377 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL8481796 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL1765841 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R | |
| SCHEMBL27638465 | 0.73 | CYP11B1 (0.43) | CYP11B1CYP11B2NR1I2ADORA3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684628-B | Substituted indanyl imidazole compound, preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2025-06-17 | — | — | CN | disclosed |
| CN-118684628-A | Substituted indanyl imidazole compound, preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-09-24 | — | — | CN | disclosed |
| US-11999716-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4055013-B1 | WDR5 INHIBITORS AND MODULATORS | UNIV VANDERBILT (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-116496261-A | 4- (1H) -imidazole derivative and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-0954521-B1 | 4- (THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO MCNEIL PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6465486-B1 | ALPHA2 ADRENOCEPTOR MODULATORS; HYPERTENSION, GLAUCOMA, SEXUAL DYSFUNCTION, DEPRESSION, ATTENTION DEFICIT HYPERACTIVITY DISORDER, PARKINSONISM, NEED FOR ANESTHESIA, CARDIAC ARRYTHMIA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| US-6080870-A | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0954521-A1 | 4- (THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | Ortho-McNeil Pharmaceutical, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| CN-1195340-A | Inhibitors of farnesyl-protein transferase | MERCK & CO INC (US) | 1998-10-07 | — | — | CN | disclosed |
| US-5750720-A | ALPHA-ADRENORECEPTORS AND CENTRAL NERVOUS SYSTEMS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997035858-A1 | 4-[(THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING α2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | CYP11B1 2400/4885CYP11B2 2502/4885NR1I2 1810/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | CYP11B1 4347/4885CYP11B2 4541/4885NR1I2 1502/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | CYP11B1 3286/4885CYP11B2 3343/4885NR1I2 2873/4885 |
| US-11999716-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | CYP11B1 4316/4885CYP11B2 4456/4885NR1I2 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.